文献速递细菌感染、耐药与抗菌药物

辅助克林霉素在金黄色葡萄球菌菌血症中是否有作用?金黄色葡萄球菌网络适应性平台(SNAP)随机对照试验辅助治疗领域的方案

Does Adjunctive Clindamycin Have a Role in Staphylococcus aureus Bacteremia? A Protocol for the Adjunctive Treatment Domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) Randomized Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2024-01-01

SNAP试验是一项实用性、随机、多中心适应性平台试验,旨在同时比较不同金黄色葡萄球菌菌血症(SAB)治疗方案对90天死亡率的影响。辅助治疗领域最初比较辅助克林霉素与无辅助抗生素,计划随机分配受试者接受5天辅助克林霉素(或林可霉素)或无辅助抗生素治疗,同时联合标准抗生素治疗。

要点

  • SNAP试验为实用性、随机、多中心适应性平台试验,主要比较不同SAB治疗对90天死亡率的影响。
  • 辅助治疗领域初始比较辅助克林霉素(或林可霉素)5天与无辅助抗生素,联合标准抗生素治疗。
  • 多数SAB患者(索引血培养72小时内且无禁忌症)符合该领域入组条件。

核心结论

  • 辅助抗生素针对金黄色葡萄球菌外毒素产生的使用广泛且被许多指南推荐,但证据有限;SNAP试验辅助治疗领域旨在明确回答此问题。

研究设计与样本

  • SNAP试验为实用性、随机、多中心适应性平台试验,旨在同时比较不同SAB治疗对90天死亡率的影响。
  • 辅助治疗领域最初比较辅助克林霉素与无辅助抗生素,未来适应性调整可能纳入其他药物。
  • 受试者随机接受5天辅助克林霉素(或林可霉素)或无辅助抗生素治疗,同时联合标准抗生素治疗。
  • 多数SAB患者(索引血培养72小时内且无禁忌症)符合该领域入组条件。

关键数值与推荐

  • 预先设定的分析定义于核心方案统计附录中,领域特异性次要分析将针对克林霉素耐药、疾病表型(复杂性或非复杂性SAB)及Panton-Valentine杀白细胞素阳性分离株进行调整。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of adjunctive antibiotics directed against exotoxin production in Staphylococcus aureus bacteremia (SAB) is widespread, and it is recommended in many guidelines, but this is based on limited evidence. Existing guidelines are based on the theoretical premise of toxin suppression, as many strains of S. aureus produce toxins such as leukocidins (eg, Panton-Valentine leukocidin, toxic shock syndrome toxin 1, exfoliative toxins, and various enterotoxins). Many clinicians therefore believe that limiting exotoxin production release by S. aureus could reduce its virulence and improve clinical outcomes. Clindamycin, a protein synthesis inhibitor antibiotic, is commonly used for this purpose. We report the domain-specific protocol, embedded in a large adaptive, platform trial, seeking to definitively answer this question. METHODS AND ANALYSIS: The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a pragmatic, randomized, multicenter adaptive platform trial that aims to compare different SAB therapies, simultaneously, for 90-day mortality rates. The adjunctive treatment domain aims to test the effectiveness of adjunctive antibiotics, initially comparing clindamycin to no adjunctive antibiotic, but future adaptations may include other agents. Individuals will be randomized to receive either 5 days of adjunctive clindamycin (or lincomycin) or no adjunctive antibiotic therapy alongside standard-of-care antibiotics. Most participants with SAB (within 72 hours of index blood culture and with no contraindications) will be eligible to participate in this domain. Prespecified analyses are defined in the statistical appendix to the core protocol, and domain-specific secondary analyses will be adjusted for resistance to clindamycin, disease phenotype (complicated or uncomplicated SAB) and Panton-Valentine leukocidin-positive isolate.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Anpalagan K, Dotel R, MacFadden DR, et al. Does Adjunctive Clindamycin Have a Role in Staphylococcus aureus Bacteremia? A Protocol for the Adjunctive Treatment Domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) Randomized Controlled Trial. Clin Infect Dis. 2024. PMID: 38801783. doi:10.1093/cid/ciae289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。